<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1A07115F-DA3C-4366-B725-3E1D63406ACD"><gtr:id>1A07115F-DA3C-4366-B725-3E1D63406ACD</gtr:id><gtr:name>Cochrane (London, UK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F68FCA8D-40C8-4B06-8204-828648EB599B"><gtr:id>F68FCA8D-40C8-4B06-8204-828648EB599B</gtr:id><gtr:name>RTI International</gtr:name><gtr:address><gtr:line1>3040 Cornwallis Road</gtr:line1><gtr:postCode>27709</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/961D29D8-3665-474D-A38E-12CABAF018E0"><gtr:id>961D29D8-3665-474D-A38E-12CABAF018E0</gtr:id><gtr:name>International Initiative for Impact Evaluation (3IE)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7C6EF8D4-F9EE-4923-AC03-55AEC6164389"><gtr:id>7C6EF8D4-F9EE-4923-AC03-55AEC6164389</gtr:id><gtr:name>Paris Descartes University</gtr:name><gtr:address><gtr:line1>45 Rue Saints Perse</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8"><gtr:id>D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8</gtr:id><gtr:name>University of Ottawa</gtr:name><gtr:address><gtr:line1>550 Cumberland</gtr:line1><gtr:line4>Ottawa</gtr:line4><gtr:line5>Ontario K1N 6N5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DC180B42-8DAF-4F9F-BA07-C5462624D673"><gtr:id>DC180B42-8DAF-4F9F-BA07-C5462624D673</gtr:id><gtr:name>University of Southern Denmark Odense</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Social Medicine</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1A07115F-DA3C-4366-B725-3E1D63406ACD"><gtr:id>1A07115F-DA3C-4366-B725-3E1D63406ACD</gtr:id><gtr:name>Cochrane (London, UK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F68FCA8D-40C8-4B06-8204-828648EB599B"><gtr:id>F68FCA8D-40C8-4B06-8204-828648EB599B</gtr:id><gtr:name>RTI International</gtr:name><gtr:address><gtr:line1>3040 Cornwallis Road</gtr:line1><gtr:postCode>27709</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/961D29D8-3665-474D-A38E-12CABAF018E0"><gtr:id>961D29D8-3665-474D-A38E-12CABAF018E0</gtr:id><gtr:name>International Initiative for Impact Evaluation (3IE)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7C6EF8D4-F9EE-4923-AC03-55AEC6164389"><gtr:id>7C6EF8D4-F9EE-4923-AC03-55AEC6164389</gtr:id><gtr:name>Paris Descartes University</gtr:name><gtr:address><gtr:line1>45 Rue Saints Perse</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8"><gtr:id>D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8</gtr:id><gtr:name>University of Ottawa</gtr:name><gtr:address><gtr:line1>550 Cumberland</gtr:line1><gtr:line4>Ottawa</gtr:line4><gtr:line5>Ontario K1N 6N5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DC180B42-8DAF-4F9F-BA07-C5462624D673"><gtr:id>DC180B42-8DAF-4F9F-BA07-C5462624D673</gtr:id><gtr:name>University of Southern Denmark Odense</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7CC686D5-0916-42CC-98C9-F591994A663F"><gtr:id>7CC686D5-0916-42CC-98C9-F591994A663F</gtr:id><gtr:firstName>Su</gtr:firstName><gtr:surname>Golder</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FFE85C78-AEC0-48AE-AEFE-06D5BFA33736"><gtr:id>FFE85C78-AEC0-48AE-AEFE-06D5BFA33736</gtr:id><gtr:firstName>Sasha</gtr:firstName><gtr:surname>Shepperd</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/21B30A96-6CB6-492E-865D-7FCFA87A1D8B"><gtr:id>21B30A96-6CB6-492E-865D-7FCFA87A1D8B</gtr:id><gtr:firstName>Rebecca</gtr:firstName><gtr:otherNames>Louise</gtr:otherNames><gtr:surname>Armstrong</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/52334FBD-A1F9-4EA7-B568-79C0768153DB"><gtr:id>52334FBD-A1F9-4EA7-B568-79C0768153DB</gtr:id><gtr:firstName>Julian</gtr:firstName><gtr:otherNames>Piers</gtr:otherNames><gtr:surname>Higgins</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8109D44A-46F3-4581-8103-A0EB362234A9"><gtr:id>8109D44A-46F3-4581-8103-A0EB362234A9</gtr:id><gtr:firstName>Jelena</gtr:firstName><gtr:surname>Savovic</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5F475A93-A5C1-4161-9CDD-EB4E099C142C"><gtr:id>5F475A93-A5C1-4161-9CDD-EB4E099C142C</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Deeks</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3D63A384-98EE-4C63-B7FF-A182D68F700A"><gtr:id>3D63A384-98EE-4C63-B7FF-A182D68F700A</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Sterne</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/850BA5F8-6453-4DFB-88A9-CFAA16779D6E"><gtr:id>850BA5F8-6453-4DFB-88A9-CFAA16779D6E</gtr:id><gtr:firstName>Elizabeth</gtr:firstName><gtr:surname>Waters</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/090BE4A9-0362-4EF8-AE7F-BF3907000F31"><gtr:id>090BE4A9-0362-4EF8-AE7F-BF3907000F31</gtr:id><gtr:firstName>Barnaby</gtr:firstName><gtr:surname>Reeves</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0BF3D9B0-11EA-48BE-8B98-08544D8AB537"><gtr:id>0BF3D9B0-11EA-48BE-8B98-08544D8AB537</gtr:id><gtr:firstName>Hugh</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Waddington</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FM025209%2F1"><gtr:id>232E94FF-6089-4981-9D70-1EC178110CF8</gtr:id><gtr:title>HOD: Assessing risk of bias in non-randomized studies of interventions</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/M025209/1</gtr:grantReference><gtr:abstractText>Research studies of the effects of interventions are critical to health technology assessment. Randomized trials are widely recognized as the most robust study design, but often they are difficult or impossible to conduct, so are not available. In such situations, we must rely on non-randomized studies. These often provide the best evidence, for example, about long-term outcomes or rare events, particularly adverse effects, and about many types of organizational or public health interventions. Systematic reviews such as Cochrane Reviews and evidence assessments informing NICE guidance include various types of non-randomized studies. It is essential that methods are available to evaluate these studies, so that decisions and recommendations are based on a full understanding of the strengths and weaknesses of the evidence. We propose a methodological programme targeted at understanding these strengths and weaknesses.

The work builds on our recent development of A Cochrane Risk Of Bias Assessment Tool: Non-Randomized Studies of Interventions (ACROBAT-NRSI). We regard the new tool as a major step forward that is likely to have a profound impact on the practice of systematic reviews, guideline development and primary research. However, initial development of ACROBAT-NRSI placed emphasis on particular types of studies in which a cohort of individuals is followed over time, and has involved only limited piloting. Furthermore, our experience from developing previous tools has shown that ongoing development and refinement is a necessary part of the tool development process.

In our proposed programme of work we aim to consolidate the first version of ACROBAT-NRSI by considering its face validity, that is, whether it adequately addresses a variety of biases as they are currently understood in the literature. We will then develop the tool further so that it appropriately covers a much larger array of types of non-randomized study and approaches to their analysis, including time series studies, before-after studies and natural experiments. This will involve development of 'signalling questions' to identify potential problems in the studies. Once we have produced a revised tool we will implement it in a large number of non-randomized studies of interventions. Besides creating a useful pool of worked examples for training purposes, this will allow us to examine the relationship between apparent problems in the studies (according to answers to the signalling questions) and the observed results of the studies, in a 'meta-epidemiology study'. Problematic studies may have systematically different results, or more variable results, than those without specific problems. Finally, we will facilitate appropriate implementation of ACROBAT-NRSI by producing an interactive, easy-to-use online version in which structure, guidance and a suite of informative examples are seamlessly integrated.</gtr:abstractText><gtr:technicalSummary>We propose a methodological programme of theoretical, applied and empirical research targeted at understanding strengths and weaknesses of non-randomized studies of the effects of interventions. The project will build on an initial version of A Cochrane Risk Of Bias Assessment Tool: Non-Randomized Studies of Interventions (ACROBAT-NRSI), which we made available in September 2014. First, we will consolidate the first version of ACROBAT-NRSI by considering its face validity. This will be achieved through formal reviews of literature relevant to its theoretical and empirical basis; and through investigation of the extent to which the tool identifies potential causes of discrepant results in specific instances where non-randomized studies and corresponding randomized trials have reached different conclusions. We will then develop ACROBAT-NRSI so that it addresses a wider variety of study designs, including time series studies, before-after studies and natural experiments, and analyses such as those based on instrumental variables and regression discontinuities. This will be done by setting up a series of working groups, culminating in a meeting of co-investigators and invited experts to decide on a revised tool version through consensus. We will then implement the revised tool in a large number of non-randomized studies within a meta-epidemiological study to examine empirically the relationship between assessments made using the tool and effect estimates. Finally, we will producing an interactive, easy-to-use online version of the revised tool in which structure, guidance and a suite of informative examples are seamlessly integrated.</gtr:technicalSummary><gtr:potentialImpactText>Who might benefit from this research?
Our research will impact directly on those undertaking systematic reviews (or other types of evidence appraisal) that include non-randomized studies on the effects of interventions, and through this will have an important impact on those making evidence-based decisions about use of healthcare interventions. This includes clinicians; patients and the public; and policy and guideline developers such as NICE as well as other decision-making organizations in the UK and abroad. Other non-academic beneficiaries include funders and commissioners of reviews.
 
How might they benefit from this research?
Systematic reviews and other evidence appraisals will use a sophisticated new tool for assessing the risk of bias in non-randomized studies. Such studies are critical for assessing long-term outcomes or rare events, particularly adverse effects, and for evaluating many types of organizational and public health intervention. Our work will allow decision-making individuals and organizations to better understand the strengths and limitations of the available research, since the tool and findings from our empirical studies will allow them to better distinguish trustworthy evidence from untrustworthy evidence. Equipped with a framework for assessing these strengths and weaknesses, we anticipate that systematic reviewers will include more evidence about harms in their reviews. These developments will lead to more informed decisions, better health outcomes and more efficient use of resources. Furthermore, funders and commissioners will be better able to consider the methodological strengths of a funding application or protocol for either a primary non-randomized study or a systematic review.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-02-28</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>365652</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Trials Unit</gtr:department><gtr:description>Risk of bias in randomized trials and non-randomized studies</gtr:description><gtr:id>156328C0-1CF3-4E04-9154-4248F4B72E1B</gtr:id><gtr:impact>This is a multidisciplinary collaboration. We have developed the ROBINS-I tool (published in the BMJ) and the RoB 2.0 tool (yet to be published but available in draft form from www.riskofbias.info.</gtr:impact><gtr:partnerContribution>Participation in regular teleconferences, emails and face-to-face meetings</gtr:partnerContribution><gtr:piContribution>Led the development of tools to assess randomized trials and non-randomized studies of interventions; and co-led the development of a tool to assess studies of exposure.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>RTI International</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Risk of bias in randomized trials and non-randomized studies</gtr:description><gtr:id>BE1E5C52-E89B-4029-A35B-572617FE1252</gtr:id><gtr:impact>This is a multidisciplinary collaboration. We have developed the ROBINS-I tool (published in the BMJ) and the RoB 2.0 tool (yet to be published but available in draft form from www.riskofbias.info.</gtr:impact><gtr:partnerContribution>Participation in regular teleconferences, emails and face-to-face meetings</gtr:partnerContribution><gtr:piContribution>Led the development of tools to assess randomized trials and non-randomized studies of interventions; and co-led the development of a tool to assess studies of exposure.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cochrane (London, UK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Risk of bias in randomized trials and non-randomized studies</gtr:description><gtr:id>624A7388-3F35-48D9-AAD1-73A738B6DDA8</gtr:id><gtr:impact>This is a multidisciplinary collaboration. We have developed the ROBINS-I tool (published in the BMJ) and the RoB 2.0 tool (yet to be published but available in draft form from www.riskofbias.info.</gtr:impact><gtr:partnerContribution>Participation in regular teleconferences, emails and face-to-face meetings</gtr:partnerContribution><gtr:piContribution>Led the development of tools to assess randomized trials and non-randomized studies of interventions; and co-led the development of a tool to assess studies of exposure.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Initiative for Impact Evaluation (3IE)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Risk of bias in randomized trials and non-randomized studies</gtr:description><gtr:id>8B4907A2-7270-43CE-B99D-80C2782095B1</gtr:id><gtr:impact>This is a multidisciplinary collaboration. We have developed the ROBINS-I tool (published in the BMJ) and the RoB 2.0 tool (yet to be published but available in draft form from www.riskofbias.info.</gtr:impact><gtr:partnerContribution>Participation in regular teleconferences, emails and face-to-face meetings</gtr:partnerContribution><gtr:piContribution>Led the development of tools to assess randomized trials and non-randomized studies of interventions; and co-led the development of a tool to assess studies of exposure.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Risk of bias in randomized trials and non-randomized studies</gtr:description><gtr:id>63C90DE5-D1DF-4D67-B07C-B23FDA4ED883</gtr:id><gtr:impact>This is a multidisciplinary collaboration. We have developed the ROBINS-I tool (published in the BMJ) and the RoB 2.0 tool (yet to be published but available in draft form from www.riskofbias.info.</gtr:impact><gtr:partnerContribution>Participation in regular teleconferences, emails and face-to-face meetings</gtr:partnerContribution><gtr:piContribution>Led the development of tools to assess randomized trials and non-randomized studies of interventions; and co-led the development of a tool to assess studies of exposure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Monash University</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Risk of bias in randomized trials and non-randomized studies</gtr:description><gtr:id>AB8FB660-0745-48C2-AD9E-E017EADAA17E</gtr:id><gtr:impact>This is a multidisciplinary collaboration. We have developed the ROBINS-I tool (published in the BMJ) and the RoB 2.0 tool (yet to be published but available in draft form from www.riskofbias.info.</gtr:impact><gtr:partnerContribution>Participation in regular teleconferences, emails and face-to-face meetings</gtr:partnerContribution><gtr:piContribution>Led the development of tools to assess randomized trials and non-randomized studies of interventions; and co-led the development of a tool to assess studies of exposure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>McGill University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Risk of bias in randomized trials and non-randomized studies</gtr:description><gtr:id>8F14C5F0-FE60-4ECE-81A5-D88E1A4336D3</gtr:id><gtr:impact>This is a multidisciplinary collaboration. We have developed the ROBINS-I tool (published in the BMJ) and the RoB 2.0 tool (yet to be published but available in draft form from www.riskofbias.info.</gtr:impact><gtr:partnerContribution>Participation in regular teleconferences, emails and face-to-face meetings</gtr:partnerContribution><gtr:piContribution>Led the development of tools to assess randomized trials and non-randomized studies of interventions; and co-led the development of a tool to assess studies of exposure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Paris - Descartes</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Risk of bias in randomized trials and non-randomized studies</gtr:description><gtr:id>E3F8B4B2-71AF-4F19-99E8-757DA3823B35</gtr:id><gtr:impact>This is a multidisciplinary collaboration. We have developed the ROBINS-I tool (published in the BMJ) and the RoB 2.0 tool (yet to be published but available in draft form from www.riskofbias.info.</gtr:impact><gtr:partnerContribution>Participation in regular teleconferences, emails and face-to-face meetings</gtr:partnerContribution><gtr:piContribution>Led the development of tools to assess randomized trials and non-randomized studies of interventions; and co-led the development of a tool to assess studies of exposure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southern Denmark Odense</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Risk of bias in randomized trials and non-randomized studies</gtr:description><gtr:id>DBDB1582-0BD8-4913-AB62-9B7119FB73F5</gtr:id><gtr:impact>This is a multidisciplinary collaboration. We have developed the ROBINS-I tool (published in the BMJ) and the RoB 2.0 tool (yet to be published but available in draft form from www.riskofbias.info.</gtr:impact><gtr:partnerContribution>Participation in regular teleconferences, emails and face-to-face meetings</gtr:partnerContribution><gtr:piContribution>Led the development of tools to assess randomized trials and non-randomized studies of interventions; and co-led the development of a tool to assess studies of exposure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Risk of bias in randomized trials and non-randomized studies</gtr:description><gtr:id>A6893075-6F7C-424D-A267-E760E3732A04</gtr:id><gtr:impact>This is a multidisciplinary collaboration. We have developed the ROBINS-I tool (published in the BMJ) and the RoB 2.0 tool (yet to be published but available in draft form from www.riskofbias.info.</gtr:impact><gtr:partnerContribution>Participation in regular teleconferences, emails and face-to-face meetings</gtr:partnerContribution><gtr:piContribution>Led the development of tools to assess randomized trials and non-randomized studies of interventions; and co-led the development of a tool to assess studies of exposure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ottawa</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Risk of bias in randomized trials and non-randomized studies</gtr:description><gtr:id>19E5EDAC-C862-4595-AE16-C6611D3257E1</gtr:id><gtr:impact>This is a multidisciplinary collaboration. We have developed the ROBINS-I tool (published in the BMJ) and the RoB 2.0 tool (yet to be published but available in draft form from www.riskofbias.info.</gtr:impact><gtr:partnerContribution>Participation in regular teleconferences, emails and face-to-face meetings</gtr:partnerContribution><gtr:piContribution>Led the development of tools to assess randomized trials and non-randomized studies of interventions; and co-led the development of a tool to assess studies of exposure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Risk of bias in randomized trials and non-randomized studies</gtr:description><gtr:id>58427BC3-2151-40DB-B888-15D236FF949C</gtr:id><gtr:impact>This is a multidisciplinary collaboration. We have developed the ROBINS-I tool (published in the BMJ) and the RoB 2.0 tool (yet to be published but available in draft form from www.riskofbias.info.</gtr:impact><gtr:partnerContribution>Participation in regular teleconferences, emails and face-to-face meetings</gtr:partnerContribution><gtr:piContribution>Led the development of tools to assess randomized trials and non-randomized studies of interventions; and co-led the development of a tool to assess studies of exposure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>National Institute of Environmental Health Sciences (NIEHS)</gtr:department><gtr:description>Risk of bias in randomized trials and non-randomized studies</gtr:description><gtr:id>D6B10A95-C252-411F-88A3-15FC8A239862</gtr:id><gtr:impact>This is a multidisciplinary collaboration. We have developed the ROBINS-I tool (published in the BMJ) and the RoB 2.0 tool (yet to be published but available in draft form from www.riskofbias.info.</gtr:impact><gtr:partnerContribution>Participation in regular teleconferences, emails and face-to-face meetings</gtr:partnerContribution><gtr:piContribution>Led the development of tools to assess randomized trials and non-randomized studies of interventions; and co-led the development of a tool to assess studies of exposure.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>TV show, Brazil</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F4AB2085-2947-4705-BCB9-D5A97313E7B3</gtr:id><gtr:impact>I was the interview subject for an edition of &amp;quot;Medicina Baseada em Evid&amp;ecirc;ncias&amp;quot;, a 30-minute TV show in Brazil hosted by Alvaro Atallah and broadcast on 28 public open channels in Brazil; first broadcast 5 May 2016; estimated audience 100,000 viewers.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>91000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Systematic Review Fellowship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>15F148B4-2DB9-4CAC-BDF1-3A7A61CF23EA</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A tool for assessing risk of bias in the result of a non-randomized study of an intervention</gtr:description><gtr:id>B15B053A-C280-45FF-8A3B-6D33399DAAE4</gtr:id><gtr:impact>BMJ paper published in 2016. Altmetric score was over 270 after four months.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Risk of bias tool for non-randomized studies of interventions (ROBINS-I)</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:url>http://www.riskofbias.info</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8A81AAA5-D844-42F0-8F48-E5FA5A272439"><gtr:id>8A81AAA5-D844-42F0-8F48-E5FA5A272439</gtr:id><gtr:title>Biases in Randomized Trials: A Conversation Between Trialists and Epidemiologists.</gtr:title><gtr:parentPublicationTitle>Epidemiology (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6e6de010625920f68bdc1a23b8975805"><gtr:id>6e6de010625920f68bdc1a23b8975805</gtr:id><gtr:otherNames>Mansournia MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1044-3983</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3626B074-58D0-434C-99C4-B66BF006FAF2"><gtr:id>3626B074-58D0-434C-99C4-B66BF006FAF2</gtr:id><gtr:title>Rethinking the assessment of risk of bias due to selective reporting: a cross-sectional study.</gtr:title><gtr:parentPublicationTitle>Systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c31fe7bba76c60899a5429efe9fde2d"><gtr:id>9c31fe7bba76c60899a5429efe9fde2d</gtr:id><gtr:otherNames>Page MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2046-4053</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/772E744D-D17F-4052-BB03-D320B21948FF"><gtr:id>772E744D-D17F-4052-BB03-D320B21948FF</gtr:id><gtr:title>Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c31fe7bba76c60899a5429efe9fde2d"><gtr:id>9c31fe7bba76c60899a5429efe9fde2d</gtr:id><gtr:otherNames>Page MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2019D690-6960-4372-AD38-7215C52AB9CB"><gtr:id>2019D690-6960-4372-AD38-7215C52AB9CB</gtr:id><gtr:title>Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/62f63221dc061f0b790a217a27e32074"><gtr:id>62f63221dc061f0b790a217a27e32074</gtr:id><gtr:otherNames>Higgins JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/83BF49CF-FB52-4B06-A872-3857D843F4D1"><gtr:id>83BF49CF-FB52-4B06-A872-3857D843F4D1</gtr:id><gtr:title>ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/da567e0749728cb450f3e0581d24435d"><gtr:id>da567e0749728cb450f3e0581d24435d</gtr:id><gtr:otherNames>Sterne JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M025209/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>12A0B409-0C29-4056-9092-2D86E44017F3</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.4  Methodologies and measurements</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>FB395309-E202-4FE8-87B0-041A3D72D4D4</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.5  Research design and methodologies (aetiology)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>